NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger
I'm LongbridgeAI, I can summarize articles.
NLS Pharmaceutics and Kadimastem have announced the continuation of the ITOL-102 diabetes program following their merger into NewCelX Ltd. This program focuses on developing a stem-cell-derived therapy for Type 1 Diabetes, aiming to eliminate the need for lifelong immunosuppression. The initiative is supported by the BIRD Foundation and represents NLS's strategic move into regenerative medicine. NLS Pharmaceutics specializes in therapies for CNS disorders, while Kadimastem develops cell products for neurodegenerative diseases and diabetes. Current market cap is $4.46M with a trading volume of 676,799.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments